Clinical Trials Browser

Interventional × Neoplasms × Afatinib × Clear all

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Phase 1/2 Active not recruiting

731 enrolled 2 FDA

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00748709 2025-02-11

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Phase 2 Terminated

20 enrolled 11 charts

Neoplasms

NCT01214616 2025-02-07

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

Phase 1 Completed

17 enrolled 15 charts

Neoplasms

NCT02171650 2025-01-23

BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01320280 2022-07-01

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Phase 2 Terminated

Neoplasms, Prostatic Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT02145637 2019-03-29

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Lung Neoplasms, Neoplasms

NCT01206816 2019-02-01

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Phase 1 Completed

57 enrolled 19 charts

Neoplasms

NCT02020577 2017-06-22

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Phase 1 Completed

58 enrolled 13 charts

Neoplasms

NCT00809133 2016-03-14

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Phase 1 Completed

83 enrolled 42 charts

Neoplasms

NCT02171663 2015-01-28

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171637 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171702 2014-06-24

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Phase 1 Completed

Neoplasms

NCT02171728 2014-06-24

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01169675 2014-06-09

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Phase 1 Completed

53 enrolled 15 charts

Neoplasms

NCT00875433 2013-12-30

Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

Phase 2 Completed

60 enrolled 26 charts

Neoplasms

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Phase 1 Completed

Neoplasms